Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 333

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 333
---
 be no assurance that we will be able to successfully consummate any particular strategic transaction. The process of continuing to evaluate these strategic options may be very costly, time-consuming and complex and we may incur significant costs related to this continued evaluation. We may also incur additional unanticipated expenses in connection with this process. A considerable portion of these costs will be incurred regardless of whether any such course of action is implemented or transaction is completed. Any such expenses will decrease the remaining cash available for use in our business and may diminish or delay any future distributions to our stockholders. In addition, there can be no assurances that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated, lead to increased stockholder value, or achieve the anticipated results. Any failure of such potential transaction to achieve the anticipated results could significantly impair our ability to enter into any future strategic transactions and may significantly reduce or delay any future distributions to our stockholders. If we are successful in completing a strategic transaction, we may be exposed to other operational and financial risks. Although there can be no assurance that a strategic transaction will result from the process we have undertaken to assess strategic options, the negotiation and consummation of any such transaction will require significant time on the part of our management, and the diversion of management’s attention may disrupt the orderly operation of our company. The negotiation and consummation of any such transaction may also require more time or greater cash resources than we anticipate and expose us to other operational and financial risks, including:

| • |     | increased near-term and long-term expenditures; |

| • |     | exposure to unknown liabilities; |

- 229 -

| • |     | higher than expected acquisition, disposition or integration costs; |

| • |     | incurrence of substantial debt or dilutive issuances of equity securities to fund future operations; |

| • |     | write-downs of assets or incurrence of non-recurring, impairment or other 
 charges;                                                                  |

| • |     | difficulty and cost in combining the operations and personnel of any acquired business with our operations and 
 personnel;                                                                                                     |

| • |     | impairment of relationships with key suppliers or customers of any acquired business due to changes in management 
 and ownership;                                                                                                    |

| • |     | inability to retain key employees of our company or any acquired business; and |

| • |     | possibility of future litigation. |

Any of the foregoing risks could have a material adverse effect on our business, financial condition and